# Bioequivalence of Bicalutamide New Formulation in Japan

> **NCT01416870** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 102 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ICI176,334-1
- **DRUG:** Casodex 80 mg tablet

## Key facts

- **NCT ID:** NCT01416870
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2012-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416870, "Bioequivalence of Bicalutamide New Formulation in Japan". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01416870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*